Clinical Trial Update: A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial update for CS1001 in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• CS1001

Snippet

Sponsor: CStone Pharmaceuticals | Conditions: Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | Status: COMPLETED